Atricure Intrinsic Value Calculator – PNC Financial Services Group Reduces Stake in AtriCure, by Selling 948 Shares
June 22, 2023
☀️Trending News
ATRICURE ($NASDAQ:ATRC): AtriCure, Inc. (ATRC) is a medical technology company that specializes in innovative treatments for atrial fibrillation and other cardiac diseases. It focuses on developing, manufacturing, and marketing surgical ablation systems designed to create precise lesions or scars in the heart tissue, resulting in improved cardiac function. PNC Financial Services Group Inc. recently sold 948 shares of AtriCure, Inc. (ATRC). The sale of the shares was done as part of PNC’s periodic trading program.
The sale of the shares has had a noticeable impact on the stock price of ATRC. Although this may be due to other factors related to the stock market, it is likely that the sale of the shares has played a role in the recent dip in the stock price. This indicates that PNC does not intend to completely exit the position and may still see value in holding a small stake in AtriCure.
Stock Price
This resulted in the stock price of AtriCure, Inc. dropping by 2.0% from the previous closing price of 48.8 to 47.9 when the markets opened. The drop in shares led to a decrease in overall market capitalization for AtriCure, Inc., although the financial impact of this move is yet to be seen. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Atricure. AtriCure_by_Selling_948_Shares”>More…
| Total Revenues | Net Income | Net Margin |
| 349.3 | -37.76 | -10.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Atricure. AtriCure_by_Selling_948_Shares”>More…
| Operations | Investing | Financing |
| -1.59 | 53.1 | -2.08 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Atricure. AtriCure_by_Selling_948_Shares”>More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 583.1 | 128.25 | 9.6 |
Key Ratios Snapshot
Some of the financial key ratios for Atricure are shown below. AtriCure_by_Selling_948_Shares”>More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 14.9% | – | -9.1% |
| FCF Margin | ROE | ROA |
| -5.0% | -4.4% | -3.4% |
Analysis – Atricure Intrinsic Value Calculator
At GoodWhale, we recently conducted an analysis of ATRICURE’s financials. After running our proprietary Valuation Line, we determined that the intrinsic value of an ATRICURE share is around $69.8. This is a significant amount higher than the price at which the stock is currently trading, which is $47.9. This indicates that ATRICURE is currently undervalued by 31.3%. AtriCure_by_Selling_948_Shares”>More…
Peers
The company was founded in 2000 and is headquartered in Mason, Ohio. AtriCure‘s competitors include Abiomed Inc, LeMaitre Vascular Inc, and Nevro Corp. These companies also provide medical devices and services for the treatment of Afib and other cardiovascular conditions.
– Abiomed Inc ($NASDAQ:ABMD)
Abiomed Inc. is a medical device company that develops and manufactures products to treat congestive heart failure and acute cardiac conditions. The company’s product portfolio includes implantable cardioverter defibrillators, left ventricular assist devices, and heart pumps. Abiomed’s products are used by hospitals and clinics around the world. The company has a market capitalization of $16.86 billion and a return on equity of 10.55%. Abiomed is headquartered in Danvers, Massachusetts.
– LeMaitre Vascular Inc ($NASDAQ:LMAT)
LeMaitre Vascular Inc is a medical device company that specializes in the manufacturing of devices and implants for the treatment of peripheral vascular diseases. The company has a market capitalization of 984.38 million as of 2022 and a return on equity of 6.77%. The company’s products are used by surgeons to treat a variety of vascular conditions, including arterial and venous diseases.
– Nevro Corp ($NYSE:NVRO)
As of 2022, Nevro Corp has a market cap of 1.44B and a Return on Equity of -34.12%. The company is a medical device company that develops and commercializes proprietary neuromodulation solutions for the treatment of chronic pain.
Summary
PNC Financial Services Group Inc. recently sold 948 shares of AtriCure, Inc., a medical device company specializing in innovative surgical ablation systems designed to create precise lesions in cardiac tissue. This suggests that the company remains confident in AtriCure, Inc.’s performance and potential value as an investment. Investors should continue to conduct their own analysis to determine whether AtriCure, Inc. is a suitable long-term investment opportunity.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
